Skip to main content
Erschienen in: Drugs & Aging 7/2014

01.07.2014 | Original Research Article

Appropriateness of Medications Prescribed to Elderly Patients with Advanced Heart Failure and Limited Life Expectancy Who Died During Hospitalization

verfasst von: Montserrat Barceló, Olga Torres, Domingo Ruiz, Jordi Casademont

Erschienen in: Drugs & Aging | Ausgabe 7/2014

Einloggen, um Zugang zu erhalten

Abstract

Background and objectives

Drug therapy in patients with advanced heart failure and limited life expectancy may be of no benefit or even inappropriate. The aim of this study was to analyze the appropriateness of medication prescribed to patients with advanced heart failure and limited life expectancy, considering as such an expected median survival of less than 6 months.

Methods

We retrospectively reviewed data on all patients with advanced heart failure who met criteria for limited life expectancy and who died in the geriatric ward of a tertiary hospital over a four-and-a-half-year period. We analyzed treatments prescribed before admission, especially drugs used for prophylaxis or to prolong life.

Results

A total of 72 patients were included. The mean age was 85.4 years, and 52.3 % were women. Mean Charlson index was 3.2. Prophylactic medications taken by patients at admission were antiplatelets in 40 patients (55.6 %), oral anticoagulants in 17 (23.6 %), statins in 14 (19.4 %), and osteoporosis medication in nine (12.5 %). Medications taken to prolong survival were angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists in 29 patients (40.3 %). Other medications were iron supplements in 19 patients (26.4 %), vitamins in two (2.8 %), and acetylcholinesterase inhibitors in two (2.8 %).

Conclusions

Our results show that patients with advanced heart failure and limited life expectancy were receiving an excessive number of prophylactic medications, drugs to prolong life, and other inappropriate treatments. These findings emphasize the need to review drug therapy in an individualized manner in elderly patients with advanced stages of heart disease and a poor prognosis.
Literatur
1.
Zurück zum Zitat Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 128:e240–7; originally published online June 5, doi:10.1161/CIR.0b013e31829e8776. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 128:e240–7; originally published online June 5, doi:10.​1161/​CIR.​0b013e31829e8776​.
2.
Zurück zum Zitat Salpeter SR, Luo EJ, Malter DS, et al. Systematic review of noncancer presentations with a median survival of 6 months or less. Am J Med. 2012; 125 (5):512.e1–16. Salpeter SR, Luo EJ, Malter DS, et al. Systematic review of noncancer presentations with a median survival of 6 months or less. Am J Med. 2012; 125 (5):512.e1–16.
3.
Zurück zum Zitat Cruz-Jentoft A, Boland B, Rexach L. Drug therapy optimization at the end of life. Drugs Aging. 2012;29(6):511–21.PubMedCrossRef Cruz-Jentoft A, Boland B, Rexach L. Drug therapy optimization at the end of life. Drugs Aging. 2012;29(6):511–21.PubMedCrossRef
4.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.PubMedCrossRef Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.PubMedCrossRef
5.
Zurück zum Zitat Katz S, Ford AB, Moskowitz RW, et al. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychological function. JAMA. 1963;185:914–9.PubMedCrossRef Katz S, Ford AB, Moskowitz RW, et al. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychological function. JAMA. 1963;185:914–9.PubMedCrossRef
6.
Zurück zum Zitat Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity and guidelines. J Clin Oncol. 1984;2(3):187–93.PubMed Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity and guidelines. J Clin Oncol. 1984;2(3):187–93.PubMed
7.
Zurück zum Zitat McKee PA, Castelli WP, McNamara PM, et al. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285(26):1441–6.PubMedCrossRef McKee PA, Castelli WP, McNamara PM, et al. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285(26):1441–6.PubMedCrossRef
8.
Zurück zum Zitat Delgado E, Muñoz M, Montero B, et al. Prescripción inapropiada de medicamentos en los pacientes mayores: los criterios STOPP/START. Rev Esp Geriatr Gerontol. 2009;44(5):273–9.CrossRef Delgado E, Muñoz M, Montero B, et al. Prescripción inapropiada de medicamentos en los pacientes mayores: los criterios STOPP/START. Rev Esp Geriatr Gerontol. 2009;44(5):273–9.CrossRef
9.
Zurück zum Zitat Mannucci PM. Thromboprophylaxis in the oldest old with atrial fibrillation: between Scylla and Charybdis. Eur J Intern Med. 2013;24:285–7.PubMedCrossRef Mannucci PM. Thromboprophylaxis in the oldest old with atrial fibrillation: between Scylla and Charybdis. Eur J Intern Med. 2013;24:285–7.PubMedCrossRef
10.
Zurück zum Zitat O’Brien CP. Withdrawing medication. Managing medical comorbidities near the end of life. Can Fam Phys. 2011; 57:304–7. O’Brien CP. Withdrawing medication. Managing medical comorbidities near the end of life. Can Fam Phys. 2011; 57:304–7.
11.
Zurück zum Zitat McMurray JJV, Adamopoulos S, Anker SD, et al. Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC. Eur Heart J. 2012;33:1787–847.PubMedCrossRef McMurray JJV, Adamopoulos S, Anker SD, et al. Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC. Eur Heart J. 2012;33:1787–847.PubMedCrossRef
12.
Zurück zum Zitat O’Mahony D, O’Connor M. Pharmacotherapy at the end of life. Age Ageing. 2011;40:419–22.PubMedCrossRef O’Mahony D, O’Connor M. Pharmacotherapy at the end of life. Age Ageing. 2011;40:419–22.PubMedCrossRef
13.
Zurück zum Zitat Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol. 1983;2:755–63.CrossRef Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol. 1983;2:755–63.CrossRef
14.
Zurück zum Zitat Holmes HM, Hayley DC, Alexander GC, et al. Reconsidering medications appropriateness for patients late in life. Arch Intern Med. 2006;166:605–9.PubMedCrossRef Holmes HM, Hayley DC, Alexander GC, et al. Reconsidering medications appropriateness for patients late in life. Arch Intern Med. 2006;166:605–9.PubMedCrossRef
15.
Zurück zum Zitat Binaray C, Califf RM, Hasselblad V, et al. ESCAPE investigators and ESCAPE study coordinators. Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness: the ESCAPE trial. JAMA. 2005;294:1625–33.CrossRef Binaray C, Califf RM, Hasselblad V, et al. ESCAPE investigators and ESCAPE study coordinators. Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness: the ESCAPE trial. JAMA. 2005;294:1625–33.CrossRef
16.
Zurück zum Zitat Goodlin SJ. Palliative care in congestive heart failure. J Am Coll Cardiol. 2009;54:386–96.PubMedCrossRef Goodlin SJ. Palliative care in congestive heart failure. J Am Coll Cardiol. 2009;54:386–96.PubMedCrossRef
17.
18.
Zurück zum Zitat Levy WC, Mozaffarian D, Linker DT, et al. The Seattle heart failure model: prediction of survival in heart failure. Circulation. 2006;113:1424–33.PubMedCrossRef Levy WC, Mozaffarian D, Linker DT, et al. The Seattle heart failure model: prediction of survival in heart failure. Circulation. 2006;113:1424–33.PubMedCrossRef
19.
Zurück zum Zitat Aaronson KD, Schwartz JS, Chen TM, et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation. 1997;95:2660–7.PubMedCrossRef Aaronson KD, Schwartz JS, Chen TM, et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation. 1997;95:2660–7.PubMedCrossRef
20.
Zurück zum Zitat Fonarow GC, Adams KF Jr, Abraham WT, ADHERE Scientific Advisory Committee, Study Group, and Investigators, et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005;293:572–80.PubMedCrossRef Fonarow GC, Adams KF Jr, Abraham WT, ADHERE Scientific Advisory Committee, Study Group, and Investigators, et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005;293:572–80.PubMedCrossRef
21.
Zurück zum Zitat Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;290:2581–7.PubMedCrossRef Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;290:2581–7.PubMedCrossRef
22.
Zurück zum Zitat O’Connor CM, Hasselblad V, Mehta RH, et al. Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score. J Am Coll Cardiol. 2010;55:872–8.PubMedCrossRef O’Connor CM, Hasselblad V, Mehta RH, et al. Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score. J Am Coll Cardiol. 2010;55:872–8.PubMedCrossRef
24.
Zurück zum Zitat Gómez-Batiste X, Martinez-Muñoz M, Blay C, et al. Proyecto NECPAL CCOMS-ICO©: Instrumento para la identificación de personas en situación de enfermedad crónica avanzada y necesidad de atención paliativa en servicios de salud y sociales. Centro colaborador de la OMS para programas públicos de curas paliativas. Institut Català d’Oncologia. Available at http://www.iconcologia.net. Gómez-Batiste X, Martinez-Muñoz M, Blay C, et al. Proyecto NECPAL CCOMS-ICO©: Instrumento para la identificación de personas en situación de enfermedad crónica avanzada y necesidad de atención paliativa en servicios de salud y sociales. Centro colaborador de la OMS para programas públicos de curas paliativas. Institut Català d’Oncologia. Available at http://​www.​iconcologia.​net.
Metadaten
Titel
Appropriateness of Medications Prescribed to Elderly Patients with Advanced Heart Failure and Limited Life Expectancy Who Died During Hospitalization
verfasst von
Montserrat Barceló
Olga Torres
Domingo Ruiz
Jordi Casademont
Publikationsdatum
01.07.2014
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 7/2014
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-014-0183-3

Weitere Artikel der Ausgabe 7/2014

Drugs & Aging 7/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.